INM
NASDAQ · Pharmaceuticals
Inmed Pharmaceuticals Inc
$1.42
+0.04 (+2.90%)
Financial Highlights (FY 2026)
Revenue
28.43M
Net Income
-46,956,445
Gross Margin
34.5%
Profit Margin
-165.1%
Rev Growth
+65.6%
D/E Ratio
—
Revenue & Net Income
Margin Trends
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Gross Margin | 34.5% | 34.5% | 36.7% | 36.7% |
| Operating Margin | -160.8% | -144.7% | 22.2% | 22.3% |
| Profit Margin | -165.1% | -156.9% | 21.8% | 17.9% |
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 28.43M | 17.18M | 790.8K | 761.6K |
| Gross Profit | 9.82M | 5.93M | 290.3K | 279.5K |
| Operating Income | -45,717,006 | -24,853,703 | 175.2K | 169.9K |
| Net Income | -46,956,445 | -25,527,514 | 172.0K | 136.0K |
| Gross Margin | 34.5% | 34.5% | 36.7% | 36.7% |
| Operating Margin | -160.8% | -144.7% | 22.2% | 22.3% |
| Profit Margin | -165.1% | -156.9% | 21.8% | 17.9% |
| Rev Growth | +65.6% | +65.6% | +11.4% | +19.5% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 0 | 0 | 119.3K | 118.2K |
| Total Equity | — | — | 1.24M | 1.28M |
| D/E Ratio | — | — | 0.10 | 0.09 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | -44,492,057 | -25,531,533 | 218.3K | 221.4K |
| Free Cash Flow | — | — | 109.5K | 116.5K |